Click for best price
Postpemic Era Drugs for NonSmall Cell Lung Cancer Market Size, Share 2022
Summary
The global and Chinese economies were hit hard in 2020, and the global GDP grew by 5.9% in 2021. Although the global growth prospects improved and there was a V-shaped rebound, this does not mean that the economy has really recovered to the level before the epidemic. The vast majority of countries are still in the stage of recovery after heavy damage and are far from achieving real recovery.
2022 is a year of continuous recovery. Global supply chain disturbance, geopolitical tension, energy price fluctuation, local labor shortage and rising raw material prices will affect the resilience of economic recovery. The International Monetary Fund (IMF) predicts that the world economy will grow by 4.4% in 2022, of which the U.S. economy will grow by about 4%. Driven by China and India, Asia is expected to become the fastest growing region in the world in 2022. However, China's economic growth has slowed down. The 2022 government work report shows that the expected target of economic growth is set at about 5.5%.
According to research, China has set a growth rate of about 5.5%, which not only focuses on the speed of economic growth, but also anchors the quality of economic development. Scientific and technological innovation, economic and social digitization and green development will be the long-term goals of China's economic development. It is expected that in 2022, major economies such as the United States, Europe and China will introduce more favorable policies to drive the development of switching power supply industry.
(Post-pandemic Era)-Global Drugs for Non-Small Cell Lung Cancer Market Segment Research Report 2022?, which aims to sort out the development status and trends of the Drugs for Non-Small Cell Lung Cancer industry at home and abroad, estimate the overall market scale of the Drugs for Non-Small Cell Lung Cancer industry and the market share of major countries, Drugs for Non-Small Cell Lung Cancer industry, and study and judge the downstream market demand of Drugs for Non-Small Cell Lung Cancer through systematic research, Analyze the competition pattern of Drugs for Non-Small Cell Lung Cancer, so as to help solve the pain points of various stakeholders in Drugs for Non-Small Cell Lung Cancer industry. This industry research report combines desktop research, qualitative interviews with insiders or experts and other methods to strive for the objectivity and integrity of conclusions and data.
Regional Segmentation (Value; Revenue, USD Million, 2018-2028) of Drugs for Non-Small Cell Lung Cancer Market by Research Include
USA
Europe
China
Japan
India
Korea
Southeast Asia
Competitive Analysis; Who are the Major Players in Drugs for Non-Small Cell Lung Cancer Market?
Bristol-Myers Squibb
GlaxoSmithKline
Menarini
Sanofi
Ziopharm Oncology
Alchemia
Amgen
Apotex
BioMarin Pharmaceutical
CellAct Pharma
Cerulean Pharma
Cipla
Cornerstone Pharmaceuticals
Curis
CytRx
Eli Lilly
Exelixis
Fresenius Kabi
Genentech
Hikma Pharmaceuticals
Hospira
Intas Pharmaceuticals
Karyopharm Therapeutics
Kyowa Hakko Kirin
Ligand Pharmaceuticals
Major Type of Drugs for Non-Small Cell Lung Cancer Covered in Research report:
Radiofrequency Ablation (RFA)
Radiation Therapy
Chemotherapy
Targeted Therapies
Immunotherapy
Application Segments Covered in Research Market
Hospitals
Clinics
Other
For any other requirements, please feel free to contact us and we will provide you customized report.
| Report Attributes |
Report Details |
| Report Title |
(Post-pandemic Era)-Global Drugs for Non-Small Cell Lung Cancer Market Segment Research Report 2022 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
114 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
Table of Contents
Global Drugs for Non-Small Cell Lung Cancer Market Segment Research Report 2022
1. Research Scope
2. Market Overview
2.1 Product Introduction, Application, Picture
2.2 Global Drugs for Non-Small Cell Lung Cancer Market by Value
2.2.1 Global Drugs for Non-Small Cell Lung Cancer Revenue by Type
2.2.2 Global Drugs for Non-Small Cell Lung Cancer Market by Value
2.3 Global Drugs for Non-Small Cell Lung Cancer Market by Sales
2.3.1 Global Drugs for Non-Small Cell Lung Cancer Sales by Type
2.3.2 Global Drugs for Non-Small Cell Lung Cancer Market by Sales
3. The Major Driver of Drugs for Non-Small Cell Lung Cancer Industry
3.1 Historical & Forecast Global Drugs for Non-Small Cell Lung Cancer Sales and Revenue (2018-2028)
3.2 Largest Application for Drugs for Non-Small Cell Lung Cancer (2018-2028)
3.3 The Major Downstream Company in China Market 2022
4. Global and Regional Drugs for Non-Small Cell Lung Cancer Market
4.1 Regional Market Size in Terms of Sales (2022 & 2028)
4.2 Regional Market Share in Terms of Revenue (2022 & 2028)
4.3 Concentration Ratio (CR5& CR10) of Drugs for Non-Small Cell Lung Cancer Market
4.4 Mergers & Acquisitions, Expansion Plans
5. US Drugs for Non-Small Cell Lung Cancer Sales (2018-2028)
5.1 Current and Estimated Sales Breakdown by Type (2018-2028)
5.2 Current and Estimated Sales Breakdown by Application (2018-2028)
5.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
5.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
6. Europe Drugs for Non-Small Cell Lung Cancer Sales (2018-2028)
6.1 Current and Estimated Sales Breakdown by Type (2018-2028)
6.2 Current and Estimated Sales Breakdown by Application (2018-2028)
6.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
6.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
7. China Drugs for Non-Small Cell Lung Cancer Sales (2018-2028)
7.1 Current and Estimated Sales Breakdown by Type (2018-2028)
7.2 Current and Estimated Sales Breakdown by Application (2018-2028)
7.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
7.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
8. Japan Drugs for Non-Small Cell Lung Cancer Sales (2018-2028)
8.1 Current and Estimated Sales Breakdown by Type (2018-2028)
8.2 Current and Estimated Sales Breakdown by Application (2018-2028)
8.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
8.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
9. India Drugs for Non-Small Cell Lung Cancer Sales (2018-2028)
9.1 Current and Estimated Sales Breakdown by Type (2018-2028)
9.2 Current and Estimated Sales Breakdown by Application (2018-2028)
9.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
9.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
10. Korea Drugs for Non-Small Cell Lung Cancer Sales (2018-2028)
10.1 Current and Estimated Sales Breakdown by Type (2018-2028)
10.2 Current and Estimated Sales Breakdown by Application (2018-2028)
10.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
10.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
11. Southeast Asia Drugs for Non-Small Cell Lung Cancer Sales (2018-2028)
11.1 Current and Estimated Sales Breakdown by Type (2018-2028)
11.2 Current and Estimated Sales Breakdown by Application (2018-2028)
11.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
11.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
12. South America Drugs for Non-Small Cell Lung Cancer Sales (2018-2028)
12.1 Current and Estimated Sales Breakdown by Type (2018-2028)
12.2 Current and Estimated Sales Breakdown by Application (2018-2028)
12.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
12.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
13. Global Drugs for Non-Small Cell Lung Cancer Average Price Trend
13.1 Market Price for Each Type of Drugs for Non-Small Cell Lung Cancer in US (2018-2022)
13.2 Market Price for Each Type of Drugs for Non-Small Cell Lung Cancer in Europe (2018-2022)
13.3 Market Price for Each Type of Drugs for Non-Small Cell Lung Cancer in China (2018-2022)
13.4 Market Price for Each Type of Drugs for Non-Small Cell Lung Cancer in Japan (2018-2022)
13.5 Market Price for Each Type of Drugs for Non-Small Cell Lung Cancer in India (2018-2022)
13.6 Market Price for Each Type of Drugs for Non-Small Cell Lung Cancer in Korea (2018-2022)
13.7 Market Price for Each Type of Drugs for Non-Small Cell Lung Cancer in Southeast Asia (2018-2022)
13.8 Market Price for Each Type of Drugs for Non-Small Cell Lung Cancer in South America (2018-2022)
14. Industrial Chain (Impact of COVID-19)
14.1 Drugs for Non-Small Cell Lung Cancer Industrial Chain Analysis
14.2 Downstream
14.3 Impact of COVID-19
14.4 Post-pandemic Era
14.5 Technology Trends of Drugs for Non-Small Cell Lung Cancer
15. Drugs for Non-Small Cell Lung Cancer Competitive Landscape
15.1 Bristol-Myers Squibb
15.1.1 Bristol-Myers Squibb Company Profiles
15.1.2 Bristol-Myers Squibb Product Introduction
15.1.3 Bristol-Myers Squibb Drugs for Non-Small Cell Lung Cancer Sales, Revenue (2018-2022)
15.1.4 Strategic initiatives
15.2 GlaxoSmithKline
15.2.1 GlaxoSmithKline Company Profiles
15.2.2 GlaxoSmithKline Product Introduction
15.2.3 GlaxoSmithKline Drugs for Non-Small Cell Lung Cancer Sales, Revenue (2018-2022)
15.2.4 Strategic initiatives
15.3 Menarini
15.3.1 Menarini Company Profiles
15.3.2 Menarini Product Introduction
15.3.3 Menarini Drugs for Non-Small Cell Lung Cancer Sales, Revenue (2018-2022)
15.3.4 Strategic initiatives
15.4 Sanofi
15.4.1 Sanofi Company Profiles
15.4.2 Sanofi Product Introduction
15.4.3 Sanofi Drugs for Non-Small Cell Lung Cancer Sales, Revenue (2018-2022)
15.4.4 Strategic initiatives
15.5 Ziopharm Oncology
15.5.1 Ziopharm Oncology Company Profiles
15.5.2 Ziopharm Oncology Product Introduction
15.5.3 Ziopharm Oncology Drugs for Non-Small Cell Lung Cancer Sales, Revenue (2018-2022)
15.5.4 Strategic initiatives
15.6 Alchemia
15.6.1 Alchemia Company Profiles
15.6.2 Alchemia Product Introduction
15.6.3 Alchemia Drugs for Non-Small Cell Lung Cancer Sales, Revenue (2018-2022)
15.6.4 Strategic initiatives
15.7 Amgen
15.7.1 Amgen Company Profiles
15.7.2 Amgen Product Introduction
15.7.3 Amgen Drugs for Non-Small Cell Lung Cancer Sales, Revenue (2018-2022)
15.7.4 Strategic initiatives
15.8 Apotex
15.8.1 Apotex Company Profiles
15.8.2 Apotex Product Introduction
15.8.3 Apotex Drugs for Non-Small Cell Lung Cancer Sales, Revenue (2018-2022)
15.8.4 Strategic initiatives
15.9 BioMarin Pharmaceutical
15.9.1 BioMarin Pharmaceutical Company Profiles
15.9.2 BioMarin Pharmaceutical Product Introduction
15.9.3 BioMarin Pharmaceutical Drugs for Non-Small Cell Lung Cancer Sales, Revenue (2018-2022)
15.9.4 Strategic initiatives
15.10 CellAct Pharma
15.10.1 CellAct Pharma Company Profiles
15.10.2 CellAct Pharma Product Introduction
15.10.3 CellAct Pharma Drugs for Non-Small Cell Lung Cancer Sales, Revenue (2018-2022)
15.10.4 Strategic initiatives
15.11 Cerulean Pharma
15.12 Cipla
15.13 Cornerstone Pharmaceuticals
15.14 Curis
15.15 CytRx
15.16 Eli Lilly
15.17 Exelixis
15.18 Fresenius Kabi
15.19 Genentech
15.20 Hikma Pharmaceuticals
15.21 Hospira
15.22 Intas Pharmaceuticals
15.23 Karyopharm Therapeutics
15.24 Kyowa Hakko Kirin
15.25 Ligand Pharmaceuticals
16. Conclusion
17. Methodology and Data Source
LIST OF TABLES & FIGURES
List of Tables and Figures
Figure 1. Total Sales by Application of Drugs for Non-Small Cell Lung Cancer Industry (Volume)
Figure 2. Drugs for Non-Small Cell Lung Cancer Sales by Regions in 2022
Figure 3. Regional Market Share in Terms of Revenue (2022&2028)
Figure 4. The Top 10 and 5 Players Market Share by Drugs for Non-Small Cell Lung Cancer Revenue in 2022
Figure 5. US Drugs for Non-Small Cell Lung Cancer Sales (2018-2028)
Figure 6. Sales Breakdown by Type (%)
Figure 7. Sales Breakdown by Type (%)
Figure 8. Sales Breakdown by Application (%)
Figure 9. Revenue Breakdown by Type (%)
Figure 10. Revenue Breakdown by Application (%)
Figure 11. Europe Drugs for Non-Small Cell Lung Cancer Sales (2018-2028)
Figure 12. Sales Breakdown by Type (%)
Figure 13. Sales Breakdown by Type (%)
Figure 14. Sales Breakdown by Application (%)
Figure 15. Revenue Breakdown by Type (%)
Figure 16. Revenue Breakdown by Application (%)
Figure 17. China Drugs for Non-Small Cell Lung Cancer Sales (2018-2028)
Figure 18. Sales Breakdown by Type (%)
Figure 19. Sales Breakdown by Type (%)
Figure 20. Sales Breakdown by Application (%)
Figure 21. Current and Estimated Revenue Breakdown by Type
Figure 22. Revenue Breakdown by Type (%)
Figure 23. Revenue Breakdown by Application (%)
Figure 24. Japan Drugs for Non-Small Cell Lung Cancer Sales (2018-2028)
Figure 25. Sales Breakdown by Type (%)
Figure 26. Sales Breakdown by Type (%)
Figure 27. Sales Breakdown by Application (%)
Figure 28. Revenue Breakdown by Type (%)
Figure 29. Revenue Breakdown by Application (%)
Figure 30. India Drugs for Non-Small Cell Lung Cancer Sales (2018-2028)
Figure 31. Sales Breakdown by Type (%)
Figure 32. Sales Breakdown by Type (%)
Figure 33. Sales Breakdown by Application (%)
Figure 34. Revenue Breakdown by Type (%)
Figure 35. Revenue Breakdown by Application (%)
Figure 36. Korea Drugs for Non-Small Cell Lung Cancer Sales (2018-2028)
Figure 37. Sales Breakdown by Type (%)
Figure 38. Sales Breakdown by Type (%)
Figure 39. Sales Breakdown by Application (%)
Figure 40. Revenue Breakdown by Type (%)
Figure 41. Revenue Breakdown by Application (%)
Figure 42. Southeast Asia Drugs for Non-Small Cell Lung Cancer Sales (2018-2028)
Figure 43. Current and Estimated Sales Breakdown by Type (2018-2028)
Figure 44. Sales Breakdown by Type (%)
Figure 45. Sales Breakdown by Type (%)
Figure 46. Revenue Breakdown by Type (%)
Figure 47. Revenue Breakdown by Application (%)
Figure 48. Industrial Chain
Table 1. Top Manufacturers and Market Segmentation
Table 2. Product Introduction, Application, Picture
Table 3. Drugs for Non-Small Cell Lung Cancer Revenue, by Type (Million USD) (2018-2028)
Table 4. Drugs for Non-Small Cell Lung Cancer Sales, by Type (K Unit) (2018-2028)
Table 5. Drugs for Non-Small Cell Lung Cancer Sales (K Unit) by Application (2018-2028)
Table 6. Drugs for Non-Small Cell Lung Cancer Sales (Million USD) by Application (2018-2028)
Table 7. The Major Downstream Company in China
Table 8. Regional Market Share in Terms of Sales (2022)
Table 9. Regional Market Share in Terms of Revenue (2022&2028)
Table 10. Ranking of Global Top Drugs for Non-Small Cell Lung Cancer Companies by Revenue, Concentration Ratio in 2022
Table 11. Mergers & Acquisitions, Expansion Plans
Table 12. US Drugs for Non-Small Cell Lung Cancer Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 13. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 14. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 15. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 16. Current and Estimated Revenue Breakdown by Type
Table 17. Current and Estimated Revenue Breakdown by Application
Table 18. Europe Drugs for Non-Small Cell Lung Cancer Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 19. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 20. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 21. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 22. Current and Estimated Revenue Breakdown by Type
Table 23. Current and Estimated Revenue Breakdown by Application
Table 24. China Drugs for Non-Small Cell Lung Cancer Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 25. Table Current and Estimated Sales Breakdown by Type
Table 26. Current and Estimated Sales Breakdown by Type
Table 27. Current and Estimated Sales Breakdown by Application
Table 28. Current and Estimated Revenue Breakdown by Application
Table 29. Japan Drugs for Non-Small Cell Lung Cancer Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 30. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 31. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 32. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 33. Current and Estimated Revenue Breakdown by Type
Table 34. Current and Estimated Revenue Breakdown by Application
Table 35. India Drugs for Non-Small Cell Lung Cancer Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 36. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 37. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 38. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 39. Current and Estimated Revenue Breakdown by Type
Table 40. Current and Estimated Revenue Breakdown by Application
Table 41. Korea Drugs for Non-Small Cell Lung Cancer Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 42. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 43. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 44. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 45. Current and Estimated Revenue Breakdown by Type
Table 46. Current and Estimated Revenue Breakdown by Application
Table 47. Southeast Asia Drugs for Non-Small Cell Lung Cancer Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 48. Table Current and Estimated Sales Breakdown by Type (2018-2028)
Table 49. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 50. Current and Estimated Revenue Breakdown by Type
Table 51. Current and Estimated Revenue Breakdown by Application
Table 52. Market Price (USD/Unit) for Each Type of Drugs for Non-Small Cell Lung Cancer in US (2018-2022)
Table 53. Market Price (USD/Unit) for Each Type of Drugs for Non-Small Cell Lung Cancer in Europe (2018-2022)
Table 54. Market Price (USD/Unit) for Each Type of Drugs for Non-Small Cell Lung Cancer in China (2018-2022)
Table 55. Market Price (USD/Unit) for Each Type of Drugs for Non-Small Cell Lung Cancer in Japan (2018-2022)
Table 56. Market Price (USD/Unit) for Each Type of Drugs for Non-Small Cell Lung Cancer in India (2018-2022)
Table 57. Market Price (USD/Unit) for Each Type of Drugs for Non-Small Cell Lung Cancer in Korea (2018-2022)
Table 58. Market Price (USD/Unit) for Each Type of Drugs for Non-Small Cell Lung Cancer in Southeast Asia (2018-2022)
Table 59. Key Downstream Customer in Each Application Field
Table 60. Bristol-Myers Squibb Profiles
Table 61. Bristol-Myers Squibb Drugs for Non-Small Cell Lung Cancer Product Introduction
Table 62. Bristol-Myers Squibb Drugs for Non-Small Cell Lung Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 63. Bristol-Myers Squibb Strategic initiatives
Table 64. GlaxoSmithKline Profiles
Table 65. GlaxoSmithKline Drugs for Non-Small Cell Lung Cancer Product Introduction
Table 66. GlaxoSmithKline Drugs for Non-Small Cell Lung Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 67. GlaxoSmithKline Strategic initiatives
Table 68. Menarini Profiles
Table 69. Menarini Drugs for Non-Small Cell Lung Cancer Product Introduction
Table 70. Menarini Drugs for Non-Small Cell Lung Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 71. Menarini Strategic initiatives
Table 72. Sanofi Profiles
Table 73. Sanofi Drugs for Non-Small Cell Lung Cancer Product Introduction
Table 74. Sanofi Drugs for Non-Small Cell Lung Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 75. Sanofi Strategic initiatives
Table 76. Ziopharm Oncology Profiles
Table 77. Ziopharm Oncology Drugs for Non-Small Cell Lung Cancer Product Introduction
Table 78. Ziopharm Oncology Drugs for Non-Small Cell Lung Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 79. Ziopharm Oncology Strategic initiatives
Table 80. Alchemia Profiles
Table 81. Alchemia Drugs for Non-Small Cell Lung Cancer Product Introduction
Table 82. Alchemia Drugs for Non-Small Cell Lung Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 83. Alchemia Strategic initiatives
Table 84. Amgen Profiles
Table 85. Amgen Drugs for Non-Small Cell Lung Cancer Product Introduction
Table 86. Amgen Drugs for Non-Small Cell Lung Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 87. Amgen Strategic initiatives
Table 88. Apotex Profiles
Table 89. Apotex Drugs for Non-Small Cell Lung Cancer Product Introduction
Table 90. Apotex Drugs for Non-Small Cell Lung Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 91. Apotex Strategic initiatives
Table 92. BioMarin Pharmaceutical Profiles
Table 93. BioMarin Pharmaceutical Drugs for Non-Small Cell Lung Cancer Product Introduction
Table 94. BioMarin Pharmaceutical Drugs for Non-Small Cell Lung Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 95. BioMarin Pharmaceutical Strategic initiatives
Table 97. CellAct Pharma Profiles
Table 98. CellAct Pharma Drugs for Non-Small Cell Lung Cancer Product Introduction
Table 99. CellAct Pharma Drugs for Non-Small Cell Lung Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 100. CellAct Pharma Strategic initiatives
Table 101. Cerulean Pharma Profiles
Table 102. Cerulean Pharma Drugs for Non-Small Cell Lung Cancer Product Introduction
Table 103. Cerulean Pharma Drugs for Non-Small Cell Lung Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 104. Cerulean Pharma Strategic initiatives
Table 105. Cipla Profiles
Table 106. Cipla Drugs for Non-Small Cell Lung Cancer Product Introduction
Table 107. Cipla Drugs for Non-Small Cell Lung Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 108. Cipla Strategic initiatives
Table 109. Cornerstone Pharmaceuticals Profiles
Table 110. Cornerstone Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product Introduction
Table 111. Cornerstone Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 112. Cornerstone Pharmaceuticals Strategic initiatives
Table 113. Curis Profiles
Table 114. Curis Drugs for Non-Small Cell Lung Cancer Product Introduction
Table 115. Curis Drugs for Non-Small Cell Lung Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 116. Curis Strategic initiatives
Table 117. CytRx Profiles
Table 118. CytRx Drugs for Non-Small Cell Lung Cancer Product Introduction
Table 119. CytRx Drugs for Non-Small Cell Lung Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 120. CytRx Strategic initiatives
Table 121. Eli Lilly Profiles
Table 122. Eli Lilly Drugs for Non-Small Cell Lung Cancer Product Introduction
Table 123. Eli Lilly Drugs for Non-Small Cell Lung Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 124. Eli Lilly Strategic initiatives
Table 125. Exelixis Profiles
Table 126. Exelixis Drugs for Non-Small Cell Lung Cancer Product Introduction
Table 127. Exelixis Drugs for Non-Small Cell Lung Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 128. Exelixis Strategic initiatives
Table 129. Fresenius Kabi Profiles
Table 130. Fresenius Kabi Drugs for Non-Small Cell Lung Cancer Product Introduction
Table 131. Fresenius Kabi Drugs for Non-Small Cell Lung Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 132. Fresenius Kabi Strategic initiatives
Table 133. Genentech Profiles
Table 134. Genentech Drugs for Non-Small Cell Lung Cancer Product Introduction
Table 135. Genentech Drugs for Non-Small Cell Lung Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 136. Genentech Strategic initiatives
Table 137. Hikma Pharmaceuticals Profiles
Table 138. Hikma Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product Introduction
Table 139. Hikma Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 140. Hikma Pharmaceuticals Strategic initiatives
Table 141. Hospira Profiles
Table 142. Hospira Drugs for Non-Small Cell Lung Cancer Product Introduction
Table 143. Hospira Drugs for Non-Small Cell Lung Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 144. Hospira Strategic initiatives
Table 145. Intas Pharmaceuticals Profiles
Table 146. Intas Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product Introduction
Table 147. Intas Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 148. Intas Pharmaceuticals Strategic initiatives
Table 149. Karyopharm Therapeutics Profiles
Table 150. Karyopharm Therapeutics Drugs for Non-Small Cell Lung Cancer Product Introduction
Table 151. Karyopharm Therapeutics Drugs for Non-Small Cell Lung Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 152. Karyopharm Therapeutics Strategic initiatives
Table 153. Kyowa Hakko Kirin Profiles
Table 154. Kyowa Hakko Kirin Drugs for Non-Small Cell Lung Cancer Product Introduction
Table 155. Kyowa Hakko Kirin Drugs for Non-Small Cell Lung Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 156. Kyowa Hakko Kirin Strategic initiatives
Table 157. Ligand Pharmaceuticals Profiles
Table 158. Ligand Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product Introduction
Table 159. Ligand Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 160. Ligand Pharmaceuticals Strategic initiatives
